Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview.
暂无分享,去创建一个
[1] A. Wear. CIRCULATION , 1964, The Lancet.
[2] JosephLoscalzo. Folate and Nitrate-Induced Endothelial Dysfunction , 2001 .
[3] J. Loscalzo. Folate and nitrate-induced endothelial dysfunction: a simple treatment for a complex pathobiology. , 2001, Circulation.
[4] C. Remacle,et al. S-nitrosothiols do not induce oxidative stress, contrary to other nitric oxide donors, in cultures of vascular endothelial or smooth muscle cells. , 2001, European journal of pharmacology.
[5] W. Simmons,et al. Bradykinin metabolism in the isolated perfused rabbit heart , 2001, Journal of hypertension.
[6] J. Loscalzo. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. , 2001, Circulation research.
[7] M. Tantucci,et al. Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat , 2001, Neuroscience Letters.
[8] C. Napoli,et al. Nitric oxide and atherosclerosis. , 2001, Nitric oxide : biology and chemistry.
[9] L. Ignarro,et al. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[10] C. Napoli,et al. Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[11] L. Lerman,et al. Simvastatin Preserves Coronary Endothelial Function in Hypercholesterolemia in the Absence of Lipid Lowering , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[12] R. Kloner,et al. Sex and the patient with cardiovascular risk factors: focus on sildenafil. , 2000, The American journal of medicine.
[13] K. Muraki,et al. Nifedipine and nisoldipine modulate membrane potential of vascular endothelium via a myo-endothelial pathway. , 2000, Life sciences.
[14] S. King,et al. P-Nitrosophosphate compounds: new N-O heterodienophiles and nitroxyl delivery agents. , 2000, The Journal of organic chemistry.
[15] H. Birnboim,et al. Depletion of intracellular glutathione reduces mutations by nitric oxide-donating drugs. , 2000, Nitric oxide : biology and chemistry.
[16] D. Garvey,et al. Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. , 2000, Journal of medicinal chemistry.
[17] M. Simons. Molecular multitasking: statins lead to more arteries, less plaque , 2000, Nature Medicine.
[18] I. Shiojima,et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.
[19] K. Takeuchi,et al. Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats. , 2000, Life sciences.
[20] D. Webb,et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. , 2000, Journal of the American College of Cardiology.
[21] M. Emerson,et al. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. , 2000, European journal of pharmacology.
[22] L. Keefer,et al. Diazeniumdiolates: pro- and antioxidant applications of the "NONOates". , 2000, Free radical biology & medicine.
[23] J. Loscalzo. What we know and don't know about L-arginine and NO. , 2000, Circulation.
[24] E. Edelman,et al. Local drug delivery: an emerging approach in the treatment of restenosis , 2000, Vascular medicine.
[25] N. Vaziri,et al. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. , 2000, The Journal of pharmacology and experimental therapeutics.
[26] U. Förstermann,et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. , 2000, Circulation research.
[27] M. Rand,et al. Differential actions of L‐cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta , 2000, British journal of pharmacology.
[28] G. Welch,et al. Nitric Oxide and the Cardiovascular System , 2000, Contemporary Cardiology.
[29] T. Ogihara,et al. Pranidipine enhances the action of nitric oxide released from endothelial cells. , 2000, Hypertension.
[30] C. Napoli,et al. Nitric oxide as a signaling molecule in the vascular system: an overview. , 1999, Journal of cardiovascular pharmacology.
[31] J. Viikari,et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. , 1999, Atherosclerosis.
[32] J. Leza,et al. Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurones , 1999, Neuropharmacology.
[33] R. Weiss,et al. Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. , 1999, Journal of the American Society of Nephrology : JASN.
[34] W. Linz,et al. Interactions among ACE, kinins and NO. , 1999, Cardiovascular research.
[35] G. Kojda,et al. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. , 1999, Cardiovascular research.
[36] R. Sorrentino,et al. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. , 1999, Trends in pharmacological sciences.
[37] D. Garvey,et al. Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists as potential agents for the treatment of impotence. , 1999, The Journal of pharmacology and experimental therapeutics.
[38] K. Schönafinger. Heterocyclic NO prodrugs. , 1999, Farmaco.
[39] H. Jo,et al. Biological aspects of reactive nitrogen species. , 1999, Biochimica et biophysica acta.
[40] J. Zweier,et al. Non-enzymatic nitric oxide synthesis in biological systems. , 1999, Biochimica et biophysica acta.
[41] J. Loscalzo,et al. The potent platelet inhibitory effects of S-nitrosated albumin coating of artificial surfaces. , 1999, Journal of the American College of Cardiology.
[42] I. Osterloh,et al. Overall cardiovascular profile of sildenafil citrate. , 1999, The American journal of cardiology.
[43] J. Loscalzo,et al. Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. , 1999, The Journal of clinical investigation.
[44] J. Wallace,et al. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. , 1999, Thrombosis research.
[45] P. Vanhoutte,et al. Endothelial dysfunction: from physiology to therapy. , 1999, Journal of molecular and cellular cardiology.
[46] A. Kurtz,et al. Role of nitric oxide in the control of renin secretion. , 1998, American journal of physiology. Renal physiology.
[47] R. Brilli,et al. Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury. , 1998, American journal of respiratory and critical care medicine.
[48] E. Schiffrin. Vascular protection with newer antihypertensive agents. , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[49] D. Anderson,et al. Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate. , 1998, Biochemical pharmacology.
[50] P. Vanhoutte. Endothelial dysfunction and inhibition of converting enzyme. , 1998, European heart journal.
[51] D. Wink,et al. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. , 1998, Free radical biology & medicine.
[52] J. Tardif,et al. Biocompatibility aspects of new stent technology. , 1998, Journal of the American College of Cardiology.
[53] K. Takeuchi,et al. Role of Nitric Oxide in Pathogenesis of Aspirin-Induced Gastric Mucosal Damage in Rats , 1998, Digestion.
[54] M. Moskowitz,et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[55] M. Feelisch. The use of nitric oxide donors in pharmacological studies , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.
[56] T. Gupta,et al. Role of Nitric Oxide , 1998, Digestion.
[57] A. M. Wheatley,et al. Intrahepatic Modulation of Portal Pressure and Its Role in Portal Hypertension , 1998, Digestion.
[58] L. Nelin,et al. The use of inhaled nitric oxide in a wide variety of clinical problems. , 1998, Pediatric clinics of North America.
[59] U. Laufs,et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.
[60] A. Lechi,et al. NO‐Aspirins: Antithrombotic Activity of Derivatives of Acetyl Salicylic Acid Releasing Nitric Oxide , 1998 .
[61] F. Bernini,et al. Direct vascular effects of HMG-CoA reductase inhibitors. , 1997, Atherosclerosis.
[62] M. Flather,et al. Complete and incomplete revascularization in multivessel PTCA: what is the clinical impact? , 1998, European heart journal.
[63] F. Murad. Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? , 1998, Recent progress in hormone research.
[64] U. Laufs,et al. Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation of Endothelial Nitric Oxide Synthase* , 1997, The Journal of Biological Chemistry.
[65] J. Wallace,et al. Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils. , 1997, American journal of physiology. Gastrointestinal and liver physiology.
[66] D. Smith,et al. Incorporation of nitric oxide-releasing crosslinked polyethyleneimine microspheres into vascular grafts. , 1997, Journal of biomedical materials research.
[67] D. Garvey,et al. Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners. , 1997, The Journal of pharmacology and experimental therapeutics.
[68] L. L. Larina,et al. Urinary Nitrotyrosine Content as a Marker of Peroxynitrite-induced Tolerance to Organic Nitrates , 1997, Journal of cardiovascular pharmacology and therapeutics.
[69] P. Bellavite,et al. The Antiplatelet Effects of a New Nitroderivative of Acetylsalicylic Acid - An In Vitro Study of Inhibition on the Early Phase of Platelet Activation and on TXA2 Production , 1996, Thrombosis and Haemostasis.
[70] S. Rajagopalan,et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. , 1996, The Journal of clinical investigation.
[71] D. Harrison,et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.
[72] L. Fontana,et al. In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid. , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[73] K. M. Davies,et al. Nitric oxide-releasing polymers containing the [N(O)NO]- group. , 1996, Journal of medicinal chemistry.
[74] K. M. Davies,et al. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. , 1996, Methods in enzymology.
[75] J. Loscalzo,et al. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. , 1995, The Journal of clinical investigation.
[76] P. Minuz,et al. Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. , 1995, Thrombosis research.
[77] J. Ritter,et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. , 1995, The Journal of pharmacology and experimental therapeutics.
[78] Raymond C. Schneider,et al. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.
[79] C. Cockerell,et al. Nitric oxide: A physiologic messenger: Lowenstein CJ, Dinerman JL, Snyder SH. Ann Intern Med 1994;120:227–237 , 1995 .
[80] D. Harrison,et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. , 1995, The Journal of clinical investigation.
[81] I. Goldstein,et al. A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. , 1995, The Journal of urology.
[82] J. Wallace,et al. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. , 1994, Trends in pharmacological sciences.
[83] J. Stamler,et al. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. , 1994, The Journal of clinical investigation.
[84] G. Ford,et al. Nitric oxide mediated venodilator effects of nebivolol. , 1994, British journal of clinical pharmacology.
[85] C. Lowenstein,et al. Nitric Oxide: A Physiologic Messenger , 1994, Annals of Internal Medicine.
[86] S. Snyder,et al. Nitric oxide: a physiologic messenger molecule. , 1994, Annual review of biochemistry.
[87] D. Harrison,et al. Nitroglycerin metabolism in vascular tissue: role of glutathione S-transferases and relationship between NO. and NO2- formation. , 1993, The Biochemical journal.
[88] J. Stamler,et al. Biochemistry of nitric oxide and its redox-activated forms. , 1992, Science.
[89] L. Ignarro,et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. , 1992, The New England journal of medicine.
[90] J. Stamler,et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[91] Yuan-sheng Gao,et al. Nebivolol Induces Endothelium Dependent Relaxatíons of Canine Coronary Arteries , 1991, Journal of cardiovascular pharmacology.
[92] J. Loscalzo,et al. The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. , 1991, The Journal of pharmacology and experimental therapeutics.
[93] Yuan-sheng Gao,et al. Nebivolol Induces Endothelium-Dependent Relaxations of Canine Arteries , 1991 .
[94] H. Fung,et al. Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. , 1990, The Journal of pharmacology and experimental therapeutics.
[95] J. Loscalzo,et al. S-nitrosocaptopril. I. Molecular characterization and effects on the vasculature and on platelets. , 1989, The Journal of pharmacology and experimental therapeutics.
[96] F. Murad,et al. Effect of In Vivo Nitroglycerin Therapy on Endothelium‐Dependent and Independent Vascular Relaxation and Cyclic GMP Accumulation in Rat Aorta , 1987, Journal of cardiovascular pharmacology.
[97] J. Loscalzo,et al. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. , 1985, The Journal of clinical investigation.
[98] L. Ignarro,et al. Relationship between cyclic guanosine 3':5'-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. , 1981, The Journal of pharmacology and experimental therapeutics.
[99] L. Ignarro,et al. Coronary arterial relaxation and guanylate cyclase activation by cigarette smoke, N'-nitrosonornicotine and nitric oxide. , 1980, The Journal of pharmacology and experimental therapeutics.
[100] J. Parratt. Nitroglycerin--the first one hundred years: new facts about an old drug. , 1979, The Journal of pharmacy and pharmacology.
[101] James R. Parr Att,et al. Nitroglycerin—the first one hundred years: new facts about an old drug , 1979 .
[102] L. Ignarro,et al. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. , 1979, Journal of cyclic nucleotide research.
[103] P. Needleman,et al. Sulfhydryl requirement for relaxation of vascular smooth muscle. , 1973, The Journal of pharmacology and experimental therapeutics.
[104] W. Murrell. Nitro-Glycerine as a Remedy for Angina Pectoris , 1882, Glasgow Medical Journal.
[105] T. Brunton. ON THE USE OF NITRITE OF AMYL IN ANGINA PECTORIS. , 1867 .